How would you approach treatment of an early-stage lung cancer adjacent to a prior lung cancer previously treated with SBRT?

Regarding treatment of metachronous lesions in close physical proximity with repeat SBRT, I would employ some of the same concepts that I would be using if I were retreating a local failure after SBRT with repeat SBRT. In other words, I would consider location and the cumulative dose to the relevant OARs to determine efficacy and safety of the repeat regimen. In general retreatments in the same lobe of the lung that are planned with these principles in mind have not generated unusual elevated ri...